Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 50 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT02784158
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingNCT02779751Phase 1
• Conmana Combined With Thalidomide to Treat NSCLCStatus unknownNCT02778893Phase 4
• Liquid Biopsy for Detection of Driver Mutation in NSCLCStatus unknownNCT02778854
• PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLCCompletedNCT02777658
• KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)CompletedNCT02777567
• Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaTerminatedNCT02775006Phase 3
• Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLCStatus unknownNCT02771314Phase 2
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
• SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
• INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung CancerTerminatedNCT02764086Phase 1/2
• Pembrolizumab-PET ImagingCompletedNCT02760225Not applicable
• Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial OligometastasesStatus unknownNCT02759783Phase 2/3
• Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
• Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC PatientsStatus unknownNCT02758314
• Patient Navigation for Lung Cancer Screening in an Urban Safety-Net SystemCompletedNCT02758054Not applicable
• uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the LungStatus unknownNCT02755675Phase 2
• A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the EsophagusCompletedNCT02752126Not applicable
• Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or GefitinibCompletedNCT02747953Phase 2
• Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung CancerStatus unknownNCT02743923Phase 3
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedNCT02740985Phase 1
• Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?CompletedNCT02740894
• RT Plus EGFR-TKI for Wild-type NSCLCStatus unknownNCT02738983Phase 2
• Detection Cell Free DNA in Lung Cancer PatientsStatus unknownNCT02738593
• FDG PET/CT in Lung Cancer StagingCompletedNCT02738398Not applicable
• The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome DifferentiationStatus unknownNCT02737735Phase 1
• Paclitaxel Detection in NSCLC Treated With TC RegimenTerminatedNCT02737709Phase 2
• A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung CancerStatus unknownNCT02734524Phase 2
• The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung CancerStatus unknownNCT02733107Phase 2
• Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLCCompletedNCT02730897
• Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With ChemotherapyCompletedNCT02728492Phase 1
• Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK RearrangementsCompletedNCT02727335
• Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs FailureStatus unknownNCT02725918Phase 2
• Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung CancerCompletedNCT02720614Phase 2
• Blood-based Identification and Monitoring of Patients With ALK-translocated Lung CancerCompletedNCT02718651
• Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerCompletedNCT02716311Phase 2
• A Study of TAK-788 in Adults With Non-Small Cell Lung CancerActive, not recruitingNCT02716116Phase 1/2
• Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingNCT02715284Phase 1
• Circulating Tumor DNA in Patients at High Risk for Lung CancerTerminatedNCT02715102
• A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT02714608Phase 2
• The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC PatientsCompletedNCT02714335
• EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLCStatus unknownNCT02714010Phase 3
• An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer PatientsStatus unknownNCT02708667
• Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT02705339Phase 2
• A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or CholangiocarcinomaCompletedNCT02699606Phase 2
• Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerActive, not recruitingNCT02696993Phase 1/2
• Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer PatientsStatus unknownNCT02696525
• A Study of Prevalence of EGFR Mutations in Participants With NSCLCCompletedNCT02695849
• Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung CancerStatus unknownNCT02695550Phase 1
• CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation TherapyCompletedNCT02693080Phase 1
• A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02691299Phase 3
• Optical Biopsy for Thoracic Lymph Nodes.CompletedNCT02689050
• Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone MetastasesStatus unknownNCT02688686Phase 1/2
• Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung CancerTerminatedNCT02679963Phase 2
• Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung CancerWithdrawnNCT02673814Phase 2
• Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCWithdrawnNCT02672358Phase 2
• Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung CancerTerminatedNCT02671045
• Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLCStatus unknownNCT02669719Phase 2
• Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLCStatus unknownNCT02667743Phase 3
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung CancerCompletedNCT02664792Not applicable
• Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer PatientsStatus unknownNCT02663492Not applicable
• A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung CancerWithdrawnNCT02662634Phase 2
• Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)Status unknownNCT02661009
• Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UKCompletedNCT02658747
• Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung CancerCompletedNCT02655913Phase 1/2
• Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialStatus unknownNCT02655536Phase 2
• Study of Endostar Subcutaneous Injection in NSCLCStatus unknownNCT02652234Phase 1
• Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung NodulesWithdrawnNCT02651506Phase 2
• D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)Status unknownNCT02651441Phase 1/2
• Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)CompletedNCT02650700Not applicable
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsTerminatedNCT02650635Phase 1
• Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With DepressionStatus unknownNCT02650544Phase 2
• The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence MonitoringStatus unknownNCT02647164
• Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus TreatmentCompletedNCT02646020Phase 2
• Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung CancerCompletedNCT02645318
• EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI TreatmentStatus unknownNCT02644889
• Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT02642939Phase 2
• Vigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerWithdrawnNCT02639234Phase 2
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
• Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung CancerTerminatedNCT02635061Phase 1
• Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerStatus unknownNCT02633189Phase 3
• Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02629848Phase 3
• A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical ResectionCompletedNCT02629458Not applicable
• Atovaquone as Tumour HypOxia ModifierCompletedNCT02628080Early Phase 1
• The Watch the Spot TrialCompletedNCT02623712Not applicable
• A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyWithdrawnNCT02623595Phase 2
• EGFR Mutations on ctDNA in Patients With Advanced NSCLCCompletedNCT02623257
• Evaluate EGFR Mutation Status and Impact Factors in North ChinaCompletedNCT02620657
• Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and AustriaCompletedNCT02619929
• A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI FailureStatus unknownNCT02618590
• Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCTActive, not recruitingNCT02617186Not applicable
• Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerActive, not recruitingNCT02609776Phase 1
• Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 TherapyTerminatedNCT02608528
• A Prospective Multi-center Phase III Randomized Controlled TrialStatus unknownNCT02607592Phase 3
• Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by SurgeryWithdrawnNCT02607423Phase 2
• Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT02599454Phase 1
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02595944Phase 3

← Carcinoma, Non-Small-Cell Lung overview